Hemos leído sobre ... Vacunación en enf. reumáticas
-
Tsyruk O, Kaplan GG, Fortin PR, Hitchon CA, Chandran V, Larché MJ, et al. On Behalf Of The Succeed Investigative Team.
How Safe Are COVID-19 Vaccines in Individuals with Immune-Mediated Inflammatory Diseases? The SUCCEED Study.
Vaccines (Basel). 2024 Sep 8;12(9):1027. doi: 10.3390/vaccines12091027.
https://pubmed.ncbi.nlm.nih.gov/39340057/ -
Wolf AS, Bjørlykke KH, Ørbo HS, Bhandari S, Solum G, Kjønstad IF, et al.
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study.
EBioMedicine. 2024 Sep 10;108:105317. doi: 10.1016/j.ebiom.2024.105317. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/39260039/
-
Maritsi D, Dasoula F, Ziv A, Bizjak M, Balažiová B, Matošević M, et al.
Influenza vaccine uptake in juvenile idiopathic arthritis: a multi-centre cross-sectional study.
Eur J Pediatr. 2024 Jul;183(7):2937-2944. doi: 10.1007/s00431-024-05552-0. Epub 2024 Apr 15.
https://pubmed.ncbi.nlm.nih.gov/38619568/
-
Maritsi D, Dasoula F, Ziv A, Bizjak M, Balažiová B, Matošević M, et al.
Influenza vaccine uptake in juvenile idiopathic arthritis: a multi-centre cross-sectional study.
Eur J Pediatr. 2024 Jul;183(7):2937-2944. doi: 10.1007/s00431-024-05552-0. Epub 2024 Apr 15.
https://pubmed.ncbi.nlm.nih.gov/38619568/ -
Eviatar T, Pappo A, Freund T, Friedlander Y, Elkayam O, Hagin D, Heshin-Bekenstein M.
Cellular immune response to the anti-SARS-CoV-2 BNT162b2 mRNA vaccine in pediatric autoimmune inflammatory rheumatic disease patients and controls.
Clin Exp Immunol. 2024 Jul 12;217(2):167-172. doi: 10.1093/cei/uxae044.
https://pubmed.ncbi.nlm.nih.gov/38767466/ -
Savšek TŠ, Avramovič MZ, Avčin T, Korva M, Avšič-Županc T, Toplak N.
Serological response after COVID-19 infection compared to vaccination against COVID-19 in children with autoimmune rheumatic diseases.
Pediatr Rheumatol Online J. 2024 Jul 25;22(1):68. doi: 10.1186/s12969-024-01003-0.
https://pubmed.ncbi.nlm.nih.gov/39054538/
-
Farisogullari B, Lawson-Tovey S, Hyrich KL, Gossec L, Carmona L, Strangfeld A, et al; EULAR COVAX Registry.
Factors associated with disease flare following SARS-CoV-2 vaccination in people with inflammatory rheumatic and musculoskeletal diseases: results from the physician-reported EULAR Coronavirus Vaccine (COVAX) Registry.
Ann Rheum Dis. 2024 May 30:ard-2024-225869. doi: 10.1136/ard-2024-225869.
https://pubmed.ncbi.nlm.nih.gov/38816065/
-
Kopsidas I, Mentesidou L, Syggelou A, Papadimitriou M, Matsas M, Kossiva L, Maritsi DN.
Measles-specific antibodies loss after a single dose of MMR vaccine in children with oligo-articular JIA on methotrexate treatment: a single-center case-controlled study.
Rheumatol Int. 2024 Mar 18. doi: 10.1007/s00296-024-05563-y. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38498151/ -
Frodlund M, Nived P, Chatzidionysiou K, Södergren A, Klingberg E, Hansson M, et al.
The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA).
Microbiol Spectr. 2024 Mar 5:e0298123. doi: 10.1128/spectrum.02981-23. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38441463/
-
Hamad Saied M, van Straalen JW, de Roock S, Verduyn Lunel FM, de Wit J, de Rond LGH, Van Nieuwenhove E, Vastert BJ, van Montfrans JM, van Royen-Kerkhof A, de Joode-Smink GCJ, Swart JF, Wulffraat NM, Jansen MHA.
Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
Vaccine. 2024 Feb 15;42(5):1145-1153. doi: 10.1016/j.vaccine.2024.01.047.
https://pubmed.ncbi.nlm.nih.gov/38262809/
-
Hamad Saied M, van Straalen JW, de Roock S, Verduyn Lunel FM, de Wit J, de Rond LGH, et al.
Humoral and cellular immunogenicity, effectiveness and safety of COVID-19 mRNA vaccination in patients with pediatric rheumatic diseases: A prospective cohort study.
Vaccine. 2024 Jan 22:S0264-410X(24)00059-8. doi: 10.1016/j.vaccine.2024.01.047. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/38262809/
-
Geck L, Tascilar K, Simon D, Kleyer A, Schett G, Rech J.
Anti-Interleukin-1 Therapy Does Not Affect the Response to SARS-CoV-2 Vaccination and Infection in Patients with Systemic Autoinflammatory Diseases.
J Clin Med. 2023 Dec 8;12(24):7587. doi: 10.3390/jcm12247587.
https://pubmed.ncbi.nlm.nih.gov/38137656/
-
Sharanya P, Kota VR.
Vaccination of Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases - EULAR/PRES Updated Recommendations, 2021.
Indian Pediatr. 2023 Nov 15;60(11):947-950.
https://pubmed.ncbi.nlm.nih.gov/37950473/ -
Akgün Ö, Demirkan FG, Kavrul Kayaalp G, Erdemir M, Akay N, Çakmak F, Önel M, Keskindemirci G, Eker Ömeroğlu R, Gökçay EG, Aktay Ayaz N.
Vaccination coverage of children with rheumatic diseases compared with healthy controls: a retrospective case-control study.
Postgrad Med. 2023 Nov 24. doi: 10.1080/00325481.2023.2287988.
https://pubmed.ncbi.nlm.nih.gov/37997766/
-
Wroński J, Ciechomska M, Kuca-Warnawin E.
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients - Lessons learned from the COVID-19 pandemic.
Biomed Pharmacother. 2023 Sep;165:115254. doi: 10.1016/j.biopha.2023.115254.
https://pubmed.ncbi.nlm.nih.gov/37542854/ -
Alnaimat F, Sweis JJG, Jansz J, Modi Z, Prasad S, AbuHelal A, Vagts C, et al.
Vaccination in the Era of Immunosuppression.
Vaccines (Basel). 2023 Sep 1;11(9):1446. doi: 10.3390/vaccines11091446.
https://pubmed.ncbi.nlm.nih.gov/37766123/ -
Doskaliuk B, Ravichandran N, Sen P, Day J, Joshi M, Nune A, et al; COVAD study group; Chinoy H, Agarwal V, Aggarwal R, Gupta L.
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study.
Rheumatol Int. 2023 Sep;43(9):1651-1664. doi: 10.1007/s00296-023-05345-y.
https://pubmed.ncbi.nlm.nih.gov/37351634/ -
Wang J, Ma C, Li M, Gao X, Wu H, Dong W, Wei L.
Streptococcus pyogenes: Pathogenesis and the Current Status of Vaccines.
Vaccines (Basel). 2023 Sep 21;11(9):1510. doi: 10.3390/vaccines11091510.
https://pubmed.ncbi.nlm.nih.gov/37766186/
-
Hamad Saied M, van Straalen JW, de Roock S, de Joode-Smink GCJ, Verduyn Lunel FM, Swart JF, Wulffraat NM, Jansen MHA.
Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
Vaccine. 2023 Aug 23;41(37):5477-5482. doi: 10.1016/j.vaccine.2023.07.052. Epub 2023 Jul 27.
https://pubmed.ncbi.nlm.nih.gov/37516575/
-
Hamad Saied M, van Straalen JW, de Roock S, de Joode-Smink GCJ, Verduyn Lunel FM, Swart JF, Wulffraat NM, Jansen MHA.
Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
Vaccine. 2023 Aug 23;41(37):5477-5482. doi: 10.1016/j.vaccine.2023.07.052. Epub 2023 Jul 27.
https://pubmed.ncbi.nlm.nih.gov/37516575/ -
Bindoli S, Baggio C, Galozzi P, Vesentini F, Doria A, Cosma C, Padoan A, Sfriso P.
Autoinflammatory Diseases and COVID-19 Vaccination: Analysis of SARS-CoV-2 Anti-S-RBD IgG Levels in a Cohort of Patients Receiving IL-1 Inhibitors.
J Clin Med. 2023 Jul 18;12(14):4741. doi: 10.3390/jcm12144741.
https://pubmed.ncbi.nlm.nih.gov/37510856/ -
Ohm M, van Straalen JW, de Joode-Smink G, van Montfrans J, Bartels M, van Wildenbeest JG et al.
Meningococcal ACWY conjugate vaccine immunogenicity in adolescents with primary or secondary immune deficiencies, a prospective observational cohort study.
Pediatr Rheumatol Online J. 2023 Jul 20;21(1):73. doi: 10.1186/s12969-023-00846-3.
https://pubmed.ncbi.nlm.nih.gov/37475057/
-
Šinkovec Savšek T, Zajc Avramovič M, Avčin T, Korva M, Avšič Županc T, Toplak N.
Disease relapse rate in children with autoimmune rheumatic diseases after COVID-19 infection and vaccination.
Pediatr Rheumatol Online J. 2023 May 19;21(1):46. doi: 10.1186/s12969-023-00829-4.
https://pubmed.ncbi.nlm.nih.gov/37208721/ -
Ohm M, van Straalen JW, Zijlstra M, de Joode-Smink G, Jasmijn Sellies A, Swart JF, et al.
Meningococcal ACWY conjugate vaccine immunogenicity and safety in adolescents with juvenile idiopathic arthritis and inflammatory bowel disease: A prospective observational cohort study.
Vaccine. 2023 May 15:S0264-410X(23)00480-2. doi: 10.1016/j.vaccine.2023.04.056. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37198018/ - Luo X, Tao J, Pang M, Zhang Z, Tang X.
Knowledge and practices of vaccination for children with rheumatic diseases: A single-center study in China.
Hum Vaccin Immunother. 2023 May 21:2215108. doi: 10.1080/21645515.2023.2215108. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37211623/
-
Gottschalk MN, Heiland M, Nahles S, Preissner R, Petri WA, Wendy S, Preissner S.
Increased incidence of adult-onset Still's disease in association with COVID-19 vaccination and SARS-CoV-2 infection.
Orphanet J Rare Dis. 2023 Mar 10;18(1):50. doi: 10.1186/s13023-023-02651-3.
https://pubmed.ncbi.nlm.nih.gov/36899416/ -
Álvaro-Gracia JM, Sanchez-Piedra C, Culqui D, Rosello R, Garcia-Dorta A, Campos C, et al.
Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study.
RMD Open. 2023 Mar;9(1):e002936. doi: 10.1136/rmdopen-2022-002936.
https://pubmed.ncbi.nlm.nih.gov/36927849/ -
Tunitsky-Lifshitz Y, Maoz-Segal R, Niznik S, Shavit R, Haj Yahia S, Langevitz P, Agmon-Levin N.
The third dose of BNT162b2 COVID-19 vaccine is efficacious and safe for systemic lupus erythematosus patients receiving belimumab.
Lupus. 2023 Mar 23:9612033231164262. doi: 10.1177/09612033231164262. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36952594/ -
An Z, Zhou X, Li Y, Jaquith J, McCarthy-Fruin K, Sletten J, et al.
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients.
medRxiv. 2023 Mar 27:2023.03.22.23287597. doi: 10.1101/2023.03.22.23287597.
https://pubmed.ncbi.nlm.nih.gov/36993236/ -
Naveen R, Thakare DR, Kuwana M, Pauling JD, Day J, Joshi M, et al; COVAD Study Group; Aggarwal R, Gupta L, Agarwal V, Makol A.
Systemic sclerosis and COVID-19 vaccine safety: short-term insights from the global COVID-19 vaccination in autoimmune disease (COVAD) survey.
Rheumatol Int. 2023 Mar 31:1-11. doi: 10.1007/s00296-023-05310-9. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/37000295/
-
Ziv A, Heshin-Bekenstein M, Haviv R, Kivity S, Netzer D, Yaron S, Schur Y, Egert T, Egert Y, Sela Y, Hashkes PJ, Uziel Y.
Effectiveness of the BNT162b2 mRNA COVID-19 vaccine among adolescents with juvenile-onset inflammatory rheumatic diseases.
Rheumatology (Oxford). 2023 Feb 23;62(SI2):SI145-SI151. doi: 10.1093/rheumatology/keac408.
https://pubmed.ncbi.nlm.nih.gov/35920789/ -
Seo P, Winthrop K, Sawalha AH, Choi S, Park HA, Hwang W, Lee EB, Park JK.
Physician Perspectives on Vaccination in Patients With Autoimmune Inflammatory Rheumatic Diseases: An International Survey.
J Rheumatol. 2023 Feb;50(2):246-251. doi: 10.3899/jrheum.220135.
https://pubmed.ncbi.nlm.nih.gov/36319001/
-
Massaro MG, Caldarelli M, Franza L, Candelli M, Gasbarrini A, Gambassi G, Cianci R, Rigante D.
Current Evidence on Vaccinations in Pediatric and Adult Patients with Systemic Autoinflammatory Diseases.
Vaccines (Basel). 2023 Jan 10;11(1):151. doi: 10.3390/vaccines11010151.
https://pubmed.ncbi.nlm.nih.gov/36679996/ - Chighizola CB, Suardi I, Carrea G, Argolini L, Gattinara M, Marino A, Pontikaki I, Caporali R, Gerosa M.
Anti-SARS-CoV-2 vaccination in adolescent and adult patients with juvenile onset systemic lupus erythematosus: tolerability and impact on disease activity.
Rheumatology (Oxford). 2023 Jan 25:kead047. doi: 10.1093/rheumatology/kead047. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36702464/
- van Dam KPJ, Wieske L, Stalman EW, Kummer LYL, Roosen J, van Kempen ZLE, et al ; T2B! Immunity against SARS-CoV-2 study group.
Disease activity in patients with immune-mediated inflammatory diseases after SARS-CoV-2 vaccinations.
J Autoimmun. 2023 Jan 2;135:102984. doi: 10.1016/j.jaut.2022.102984. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36621174/
- Yeo JG, Teh KL, Ni Chia W, Book YX, Hoh SF, Gao X, et al.
COVID-19 mRNA vaccine immunogenicity decay and breakthrough illness in adolescents and young adults with childhood-onset rheumatic diseases.
Rheumatology (Oxford). 2023 Jan 20:kead031. doi: 10.1093/rheumatology/kead031. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/36661304/
-
Udaondo C, Cámara C, Miguel Berenguel L, Alcobendas Rueda R, Muñoz Gómez C, Millán Longo C, Díaz-Delgado B, Falces-Romero I, Díaz Almirón M, Ochando J, Méndez-Echevarría A, Remesal Camba A, Calvo C.
Humoral and cellular immune response to mRNA SARS-CoV-2 BNT162b2 vaccine in adolescents with rheumatic diseases
Pediatr Rheumatol Online J. 2022 Aug 13;20(1):64. doi: 10.1186/s12969-022-00724-4.
https://pubmed.ncbi.nlm.nih.gov/35964130/ -
Ohnishi Y, Okada S, Kawakami-Miyake A, Furuta T, Fukano R, Yasudo H, Shimokawa M, Hasegawa S.
Safety and Feasibility of Infliximab Therapy in Children With Kawasaki Disease Who Received Live Vaccinations
Pediatr Infect Dis J. 2022 Sep 1;41(9):e388-e392. doi: 10.1097/INF.0000000000003611. Epub 2022 Jul 27.
https://pubmed.ncbi.nlm.nih.gov/35895884/ -
Ziv A, Heshin-Bekenstein M, Haviv R, Kivity S, Netzer D, Yaron S, Schur Y, Egert T, Egert Y, Sela Y, Hashkes PJ, Uziel Y.
Effectiveness of the BNT162b2 mRNA COVID-19 Vaccine among Adolescents with Juvenile-onset Inflammatory Rheumatic Diseases
Rheumatology (Oxford). 2022 Aug 3:keac408. doi: 10.1093/rheumatology/keac408.
https://pubmed.ncbi.nlm.nih.gov/35920789/ -
Sen ES, Julandani D, Ramanan AV.
SARS-CoV-2 vaccinations in children and adolescents with rheumatic diseases
Rheumatology (Oxford). 2022 Aug 2:keac431. doi: 10.1093/rheumatology/keac431.
https://pubmed.ncbi.nlm.nih.gov/35916712/ -
Balažiová B, Kuková Z, Mišíková D, Novosedlíková K, Dallos T.
Real-life vaccination coverage in Slovak children with rheumatic diseases.
Front Pediatr. 2022 Aug 12;10:956136. doi: 10.3389/fped.2022.956136.
https://pubmed.ncbi.nlm.nih.gov/36034574/
-
Jansen MH, Rondaan C, Legger G, Minden K, Uziel Y, Toplak N, Maritsi D, van den Berg M, Berbers G, Bruijning P, Egert Y, Normand C, Bijl M, Foster H, Kone-Paut I, Wouters C, Ravelli A, Elkayam O, Wulffraat NM, Heijstek MW.
Efficacy, Immunogenicity and Safety of Vaccination in Pediatric Patients With Autoimmune Inflammatory Rheumatic Diseases (pedAIIRD): A Systematic Literature Review for the 2021 Update of the EULAR/PRES Recommendations.
Front Pediatr. 2022 Jul 6;10:910026. doi: 10.3389/fped.2022.910026.
https://pubmed.ncbi.nlm.nih.gov/35874582/ -
Lawson-Tovey S, Machado PM, Strangfeld A, Mateus E, Gossec L, Carmona L, et al; ; EULAR COVAX..
SARS-CoV-2 vaccine safety in adolescents with inflammatory rheumatic and musculoskeletal diseases and adults with juvenile idiopathic arthritis: data from the EULAR COVAX physician-reported registry.
RMD Open. 2022 Jul;8(2):e002322. doi: 10.1136/rmdopen-2022-002322.
https://pubmed.ncbi.nlm.nih.gov/35908834/ -
Gil-Vila A, Naveen R, Selva-O'Callaghan A, Sen P, Nune A, Gaur PS, et al; COVAD Study Group.
COVID-19 Vaccination In Autoimmune Diseases (COVAD) Study: Vaccine Safety In Idiopathic Inflammatory Myopathies.
Muscle Nerve. 2022 Jul 23:10.1002/mus.27681. doi: 10.1002/mus.27681. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35869701/
-
Jansen MHA, Rondaan C, Legger GE, Minden K, Uziel Y, Toplak N, Maritsi D et al.
EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: Update 2021.
Ann Rheum Dis. 2022 Jun 20:annrheumdis-2022-222574. doi: 10.1136/annrheumdis-2022-222574. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35725297/ -
Abhishek A, Boyton RJ, Peckham N, McKnight Á, Coates LC, Bluett J et al.
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
Lancet Respir Med. 2022 Jun 27:S2213-2600(22)00186-2. doi: 10.1016/S2213-2600(22)00186-2. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35772416/ -
Rider LG, Parks CG, Wilkerson J, Schiffenbauer AI, Kwok RK, Noroozi Farhadi et al.
Baseline factors associated with self-reported disease flares following COVID-19 vaccination among adults with systemic rheumatic disease: results from the COVID-19 global rheumatology alliance vaccine survey.
Rheumatology (Oxford). 2022 Jun 28;61(SI2):SI143-SI150. doi:10.1093/rheumatology/keac249.
https://pubmed.ncbi.nlm.nih.gov/35460240/
-
Aikawa NE, Kupa LVK, Silva CA, Saad CGS, Pasoto SG, Yuki EFN, et al.
Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine.
Rheumatology (Oxford). 2022 May 26:keac301. doi: 10.1093/rheumatology/keac301. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35639644/ -
Assawasaksakul T, Lertussavavivat T, Sathitratanacheewin S, Oudomying N, Connolly CM, Frey S, Chiang TP, Teles M, Alejo JL, Albayda J,
Safety of third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal disease.
Rheumatology (Oxford). 2022 May 18:keac298. doi: 10.1093/rheumatology/keac298. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35583259/ -
De Santis M, Motta F, Isailovic N, Clementi M, Criscuolo E, Clementi N, et al.
Dose-Dependent Impairment of the Immune Response to the Moderna-1273 mRNA Vaccine by Mycophenolate Mofetil in Patients with Rheumatic and Autoimmune Liver Diseases.
Vaccines (Basel). 2022 May 18;10(5):801. doi: 10.3390/vaccines10050801.
https://pubmed.ncbi.nlm.nih.gov/35632557/ -
Vichaiwattana P, Wanlapakorn N, et al.
Comparison of Immunogenicity and Safety of Inactivated, Adenovirus-Vectored, and Heterologous Adenovirus-Vectored/mRNA Vaccines in Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis: A Prospective Cohort Study.
Vaccines (Basel). 2022 May 26;10(6):853. doi: 10.3390/vaccines10060853.
https://pubmed.ncbi.nlm.nih.gov/35746461/
-
Cuadros EN, Calzada-Hernández J, Clemente D, Martín SG, Silveira LF, Lirola-Cruz MJ, Tagarro A, Lovillo MC, Rueda RMA, López AL, Aritziturri MS, Calvo C.
Position statement of the Spanish Society of Pediatric Rheumatology on infection screening, prophylaxis, and vaccination of pediatric patients with rheumatic diseases and immunosuppressive therapies: Part 1 (screening).
Eur J Pediatr. 2022 Mar 8. doi: 10.1007/s00431-022-04418-7. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35258699/ -
Fragoulis GE, Karamanakos A, Arida A, Bournia VK, Evangelatos G, Fanouriakis A, Fragiadaki K, Kravvariti E, Laskari K, Panopoulos S, Papazoglou N, Pappa M, Tektonidou MGG, Sfikakis PP.
Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases.
RMD Open. 2022 Mar;8(1):e002279. doi: 10.1136/rmdopen-2022-002279.
https://pubmed.ncbi.nlm.nih.gov/35246472/ -
Aikawa NE, Kupa LVK, Medeiros-Ribeiro AC, Saad CGS, Yuki EFN, Pasoto SG, et al.
Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases.
Ann Rheum Dis. 2022 Mar 11:annrheumdis-2021-222096. doi: 10.1136/annrheumdis-2021-222096. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35277389/ -
Mori S, Ueki Y, Ishiwada N.
Impact of Janus Kinase Inhibitors on Antibody Response to 13-Valent Pneumococcal Conjugate Vaccine in Patients with Rheumatoid Arthritis.
Mod Rheumatol. 2022 Mar 26:roac029. doi: 10.1093/mr/roac029. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35348759/ -
Troldborg A, Thomsen MK, Bartels LE, Andersen JB, Vils SR, Mistegaard CE, et al.
Time Since Rituximab Treatment Is Essential for Developing a Humoral Response to COVID-19 mRNA Vaccines in Patients With Rheumatic Diseases.
J Rheumatol. 2022 Mar 1:jrheum.211152. doi: 10.3899/jrheum.211152. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/35232803/
-
Heshin-Bekenstein M, Ziv A, Toplak N, Hagin D, Kadishevich D, Butbul YA, Saiag E, Kaufman A, Shefer G, Sharon O, Pel S, Elkayam O, Uziel Y.
Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications.
Rheumatology (Oxford). 2022 Feb 18:keac103. doi: 10.1093/rheumatology/keac103.
https://pubmed.ncbi.nlm.nih.gov/35179569/
-
Atagündüz P, Keser G, Soy M.
Interleukin-1 Inhibitors and Vaccination Including COVID-19 in Inflammatory Rheumatic Diseases: A Nonsystematic Review.
Front Immunol. 2022 Jan 27;12:734279. doi: 10.3389/fimmu.2021.734279.
https://pubmed.ncbi.nlm.nih.gov/35154066/ -
Marty PK, Van Keulen VP, Erskine CL, Shah M, Hummel A, Stachowitz M, Fatis S, Granger D, Block MS, Duarte-García A, Warrington KJ, Theel ES, Zhou X, Zeng H, Specks U, Escalante P, Peikert T.
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy.
Front Immunol. 2022 Jan 28;13:834981. doi: 10.3389/fimmu.2022.834981.
https://pubmed.ncbi.nlm.nih.gov/35154159/
-
Keller M, Pittet LF, Zimmermann P.
Immunogenicity and safety of routine vaccines in children and adolescents with rheumatic diseases on immunosuppressive treatment - a systematic review.
Eur J Pediatr. 2021 Dec 22;1-34. doi: 10.1007/s00431-021-04283-w. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34936010/ -
Degrava Sampaio-Barros P, Medeiros-Ribeiro AC, Luppino-Assad AP, Miossi R, Carriço da Silva H et al.
SARS-CoV-2 vaccine in patients with systemic sclerosis: Impact of disease subtype and therapy.
Rheumatology (Oxford). 2021 Dec 11;keab886. doi: 10.1093/rheumatology/keab886. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34894235/ -
Tzioufas AG, Bakasis AD, Goules AV, Bitzogli K et al.
A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases.
J Autoimmun. 2021 Dec;125:102743. doi: 10.1016/j.jaut.2021.102743. Epub 2021 Oct 28.
https://pubmed.ncbi.nlm.nih.gov/34757289/
-
Dimopoulou D, Vartzelis G, Dasoula F, Tsolia M, Maritsi D.
Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
Ann Rheum Dis. 2021 Nov 29:annrheumdis-2021-221607. doi: 10.1136/annrheumdis-2021-221607. Epub ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34844930/
-
Chiang TP, Connolly CM, Ruddy JA, Boyarsky BJ, Alejo JL, Werbel WA, Massie A, Christopher-Stine L, Garonzik-Wang J, Segev DL, Paik JJ.
Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases.
Ann Rheum Dis. 2021 Aug 24:annrheumdis-2021-221145. doi: 10.1136/annrheumdis-2021-221145. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34429320/ -
Boekel L, Steenhuis M, Hooijberg F, Besten YR, van Kempen ZLE, Kummer LY, et al.
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies.
Lancet Rheumatol. 2021 Aug 6. doi: 10.1016/S2665-9913(21)00222-8. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34396154/ -
Prendecki M, Clarke C, Edwards H, McIntyre S, Mortimer P, Gleeson S, et al.
Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression.
Ann Rheum Dis. 2021 Aug 6:annrheumdis-2021-220626. doi: 10.1136/annrheumdis-2021-220626. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34362747/ -
Wong PKK, Lahiri M, Lye DC, Johnson D, Charles PGP.
A vaccination update for rheumatologists-SARS-CoV-2, influenza and herpes zoster.
Int J Rheum Dis. 2021 Aug;24(8):979-983. doi: 10.1111/1756-185X.14179.
https://pubmed.ncbi.nlm.nih.gov/34350721/
-
Rollet-Cohen V, Mirete J, Dingulu G, Hofer F, Hofer M, Woerner A, Dommergues MA, Hentgen V.
Suboptimal vaccination coverage of recommended vaccines among French children with recurrent autoinflammatory fever syndromes: a study from the Juvenile Inflammatory Rheumatism cohort.
Clin Rheumatol. 2021 Jul;40(7):2855-2864. doi: 10.1007/s10067-020-05553-y. Epub 2021 Jan 13. PMID: 33439385.
https://pubmed.ncbi.nlm.nih.gov/33439385/
-
Jeffrey R Curtis, Sindhu R Johnson, Donald D Anthony et al.
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2
Arthritis Rheumatol. 2021 Jun 15. doi: 10.1002/art.41877. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34128356/ -
Amelia Santosa, Chuanhui Xu, Thaschawee Arkachaisri et al.
Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists
Int J Rheum Dis. 2021 Jun;24(6):746-757. doi: 10.1111/1756-185X.14107. Epub 2021 May 10
https://pubmed.ncbi.nlm.nih.gov/33973379/ -
Victoria Furer, Tali Eviatar, Devy Zisman et al.
Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study.
Ann Rheum Dis. 2021 Jun 14;annrheumdis-2021-220647. doi: 10.1136/annrheumdis-2021-220647. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34127481/ -
Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun et al.
Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2.
Ann Rheum Dis. 2021 Jun 18;annrheumdis-2021-220503. doi: 10.1136/annrheumdis-2021-220503. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/34074678/
-
Hazlewood GS, Pardo Pardo J, Barnabe C, Schieir O, Barber CEH, Bernatsky S, Colmegna I, Hitchon C, Loeb M, Mertz D, Proulx L, Richards DP, Scuccimarri R, Tugwell P, Schünemann HJ, Mirza RD, Zhou AL, Nikolic RPA, Thomas M, Chase H, Ejaredar M, Nieuwlaat R.
Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases.
J Rheumatol. 2021 May 15:jrheum.210288. doi:10.3899/jrheum.210288
https://pubmed.ncbi.nlm.nih.gov/33993119/
-
Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al.
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients with Rheumatic and Musculoskeletal Diseases - Version 1.
Arthritis Rheumatol. 2021 Mar 17. doi: 10.1002/art.41734. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33728796/ -
Arnold J, Winthrop K, Emery P.
COVID-19 vaccination and antirheumatic therapy.
Rheumatology (Oxford). 2021 Mar 12:keab223. doi: 10.1093/rheumatology/keab223. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33710296/ -
Park JK, Lee EB, Shin K, Sung YK, Kim TH, Kwon SR, et al; Korean College of Rheumatology Task Force for COVID-19 Vaccine Guidance for Patients with Autoimmune.
COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
J Korean Med Sci. 2021 Mar 29;36(12):e95. doi: 10.3346/jkms.2021.36.e95.
https://pubmed.ncbi.nlm.nih.gov/33783147/ -
Soy M, Keser G, Atagunduz P, Mutlu MY, Gunduz A, Koybaşi G, Bes C.
A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.
Clin Rheumatol. 2021 Mar 22:1-13. doi: 10.1007/s10067-021-05700-z. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/33751280/ -
Jensen L, Nielsen S, Christensen AE, Pedersen FK, Trebbien R, Kølsen Fischer T, et al.
Response to influenza vaccination in immunocompromised children with rheumatic disease: a prospective cohort study.
Pediatr Rheumatol Online J. 2021 Mar 12;19(1):26. doi: 10.1186/s12969-021-00518-0.
https://pubmed.ncbi.nlm.nih.gov/33712043/ -
Constantinou CA, Ziogas DC, Venetsanopoulou A, Gamaletsou MN, Koutsogeorgopoulou L, Barbouni A, Tzioufas AG, Sipsas NV.
A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: The power of awareness.
Vaccine. 2021 Mar 12;39(11):1593-1597. doi: 10.1016/j.vaccine.2021.02.009.
https://pubmed.ncbi.nlm.nih.gov/33610375/
-
Peracchi OA, Nicácio AAM, Yamada J, Len CA, Moraes-Pinto MI, Terreri MT.
Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
Lupus. 2021 Feb;30(2):299-306. doi: 10.1177/0961203320973263.
https://pubmed.ncbi.nlm.nih.gov/33197362/ -
Nicácio AAMF, Peracchi OAB, Yamada J, Fraga MM, Vitalle MS, de Moraes-Pinto MI, Terreri MT.
Tdap booster to adolescents with juvenile idiopathic arthritis on and off anti-TNF agents is safe and immunogenic.
Vaccine. 2021 Feb 12;39(7):1165-1172. doi: 10.1016/j.vaccine.2020.12.071. Epub 2021 Jan 19.
https://pubmed.ncbi.nlm.nih.gov/33478788/ -
Beesley RP, Costello W, Angevare SP, Wouters C, Wulffraat N, Uzie Y.
Survey of adult and paediatric rheumatology patients suggests information about COVID-19 vaccination will aid uptake.
Rheumatology (Oxford). 2021 Feb 16:keab169. doi: 10.1093/rheumatology/keab169.
https://pubmed.ncbi.nlm.nih.gov/33590835/
-
Tse HN, Borrow R, Arkwright PD.
Immune Response and Safety of Viral Vaccines in Children with Autoimmune Diseases on Immune Modulatory Drug Therapy.
Expert Rev Vaccines. 2021 Jan 28:1-13. doi: 10.1080/14760584.2021.1875825. Epub ahead of print. PMID: 33507119.
https://pubmed.ncbi.nlm.nih.gov/33507119/
-
Grein IHR, Pinto NBF, Groot N, Martins CB, Lobo A, Aikawa NE, Barbosa C, Terreri MT, da Fraga ACM, de Oliveira SKF, Sztajnbok F, Paim Marques LB, Islabão AG, Appenzeller S, Bica B, de Oliveira Sato J, Magalhães CS, Ferriani V, Pasmans H, Schepp R, van der Klis F, de Roock S, Wulffraat N, Pileggi GS.
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with juvenile dermatomyositis: a real-world multicentre study.
Pediatr Rheumatol Online J. 2020 Nov 11;18(1):87.
https://pubmed.ncbi.nlm.nih.gov/33176806/ -
Peracchi OA, Nicácio AAM, Yamada J, Len CA, Moraes-Pinto MI, Terreri MT.
Adequate tetanus but poor diphtheria and pertussis response to a Tdap booster in adolescents with juvenile systemic lupus erythematosus.
Lupus. 2020 Nov 16:961203320973263. doi: 10.1177/0961203320973263
https://pubmed.ncbi.nlm.nih.gov/33197362/
-
Ben Nessib D, Fazaa A, Miladi S, Sellami M, Ouenniche K, Souabni L, Kassab S, Chekili S, Ben Abdelghani K, Laatar A.
Do immunosuppressive agents hamper the vaccination response in patients with rheumatic diseases? A review of the literature.
Therapie. 2020 Sep 3:S0040-5957(20)30148-7. doi: 10.1016/j.therap.2020.08.002. Online ahead of print
https://pubmed.ncbi.nlm.nih.gov/32951867/ -
Figueroa-Parra G, Esquivel-Valerio JA, Santoyo-Fexas L, Moreno-Salinas A, Gamboa-Alonso CM, De Leon-Ibarra AL, Galarza-Delgado DA.
Knowledge and attitudes about influenza vaccination in rheumatic diseases patients.
Hum Vaccin Immunother. 2020 Sep 29:1-6. doi: 10.1080/21645515.2020.1816108. Online ahead of print.
https://pubmed.ncbi.nlm.nih.gov/32991221/ -
Bühler S, Jaeger VK, Eperon G, Furrer H, Fux CA, Jansen S, et al.
Safety and immunogenicity of a primary yellow fever vaccination under low-dose methotrexate therapy-a prospective multi-centre pilot study1.
J Travel Med. 2020 Sep 26;27(6):taaa126. doi: 10.1093/jtm/taaa126.
https://pubmed.ncbi.nlm.nih.gov/32729905/
-
Alfayadh NM, Gowdie PJ, Akikusa JD, Easton ML, Buttery JP.
Vaccinations Do Not Increase Arthritis Flares in Juvenile Idiopathic Arthritis: A Study of the Relationship between Routine Childhood Vaccinations on the Australian Immunisation Schedule and Arthritis Activity in Children with Juvenile Idiopathic Arthritis.
Int J Rheumatol. 2020 Aug 4;2020:1078914. doi: 10.1155/2020/1078914.
https://pubmed.ncbi.nlm.nih.gov/32831849/ -
Welzel T, Wörner A, Heininger U.Z.
Travel vaccinations in rheumatic diseases : Specific considerations in children and adults.
Rheumatol. 2020 Aug 26. doi: 10.1007/s00393-020-00852-w.
https://pubmed.ncbi.nlm.nih.gov/32845394/
-
Rotstein Grein IH, Pinto NF, Lobo A, Groot N, Sztajnbok F, da Silva CAA, Paim Marques LB, Appenzeller S, Islabão AG, Magalhães CS, de Almeida RG, Bica B, Fraga M, da Fraga ACM, Dos Santos MC, Robazzi T, Terreri MTR, Bandeira M, Pasmans H, Schepp R, van der Klis F, de Roock S, Wulffraat N, Pileggi G.
Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in patients with childhood systemic lupus erythematosus: a real-world interventional multi-centre study.
Lupus. 2020 Jul;29(8):934-942. doi: 10.1177/0961203320928406. Epub 2020 Jun 5.
https://pubmed.ncbi.nlm.nih.gov/32501172/
- Toplak N, Uziel Y.
Vaccination for Children on Biologics.
Curr Rheumatol Rep. 2020 May 20;22(7):26.
https://doi.org/10.1007/s11926-020-00905-8
- Nakafero G, Grainge MJ, Myles PR, Mallen CD, Zhang W, Doherty M, Nguyen-Van-Tam JS, Abhishek A.
Effectiveness of inactivated influenza vaccine in autoimmune rheumatic diseases treated with disease-modifying anti-rheumatic drugs.
Rheumatology (Oxford). 2020 Mar 11. pii: keaa078. doi: 10.1093/rheumatology/keaa078. [Epub ahead of print]https://www.ncbi.nlm.nih.gov/pubmed/32160295
- Bizjak M, Blazina Š, Zajc Avramovic M, Markelj G, Avcin T, Toplak N.
Vaccination coverage in children with rheumatic diseases.
Clin Exp Rheumatol. 2020 Jan-Feb;38(1):164-170. Epub 2019 Oct 2.
https://www.ncbi.nlm.nih.gov/pubmed/31577215 - Brunner HI, Tzaribachev N, Cornejo GV, Joos R, Gervais E, Cimaz R, Calvo Penadés I, Cuttica R, Lutz T, Quartier P, Gandhi Y, Nys M, Wong R, Martini A, Lovell DJ, Ruperto N; Pediatric Rheumatology Collaborative Study Group and the Paediatric Rheumatology International Trials Organisation.
Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2-5?years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept.
Pediatr Rheumatol Online J. 2020 Feb 22;18(1):19. doi: 10.1186/s12969-020-0410-x.
https://www.ncbi.nlm.nih.gov/pubmed/32087715
- Uziel Y, Moshe V, Onozo B, Kulcsár A, Tróbert-Sipos D, Akikusa JD, Salviato Pileggi G, Maritsi D, Kasapcopur O, Rodrigues M, Smerla R, Rigante D, Makay B, Atsali E, Wulffraat N, Toplak N; PReS working party of Vaccination Study Group.
Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection.
Vaccine. 2020 Jan 24. pii: S0264-410X(20)30052-9. doi: 10.1016/j.vaccine.2020.01.037. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/31987692
- Qendro T, de la Torre ML, Panopalis P, Hazel E, Ward BJ, Colmegna I, Hudson M.
Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care.
J Rheumatol. 2019 Jul 15. pii: jrheum.181376. doi: 10.3899/jrheum.181376. [Epub ahead of print]
https://www.ncbi.nlm.nih.gov/pubmed/?term=31308211
- Speth F, Hinze CH, Andel S, Mertens T, Haas JP.
Varicella-zoster-virus vaccination in immunosuppressed children with rheumatic diseases using a pre-vaccination check list.
Pediatr Rheumatol Online J. 2018 Mar 2;16(1):15.
https://www.ncbi.nlm.nih.gov/pubmed/29499726 - Jeyaratnam J, Ter Haar NM, Lachmann HJ, Kasapcopur O, Ombrello AK, Rigante D, Dedeoglu F, Baris EH, Vastert SJ, Wulffraat NM, Frenkel J.
The safety of live-attenuated vaccines in patients using IL-1 or IL-6 blockade: an international survey.
Pediatr Rheumatol Online J. 2018 Mar 21;16(1):19. doi: 10.1186/s12969-018-0235-z.
https://www.ncbi.nlm.nih.gov/pubmed/29562920
